NextDAY Cabinets Chantilly Showroom has unveiled the comprehensive 2025 Shiloh Cabinetry collection, featuring an expanded 29-page showcase that introduces paint programs, wood portfolios, and construction specifications for contractors, dealers, and builders.
The wholesale distributor’s Chantilly headquarters now displays the complete collection, which includes 25 standard Sherwin-Williams colors with unlimited custom matching capabilities, nine wood species options, and over 50 door styles ranging from traditional to ultra-modern designs. The Shiloh cabinets spec book details twelve premium quality features, including five-eighths-inch hardwood dovetail drawers, Blum TANDEM soft-close mechanisms, and three-quarters-inch plywood shelving, all backed by a 10-year warranty and KCMA certification.
“The 2025 collection represents a significant advancement in cabinet customization and quality construction,” said Dogan Goksoy, Sales Manager at NextDAY Cabinets Chantilly Showroom. “With our expanded paint program featuring trend colors like Shoji White, Quietude, and Rookwood Shutter Green, plus new Café and Slate Highlight techniques, we’re providing contractors and designers with unprecedented flexibility to meet their clients’ exact specifications.”
Advanced construction features distinguish the collection, with each cabinet incorporating premium components designed for longevity and performance. The comprehensive specifications include catalyzed conversion varnish finishes, adjustable shelving systems, and nine different overlay and inset configurations ranging from standard overlays to Modern Flush Inset designs.
The collection introduces Quarter-Sawn and Rift-Cut White Oak among its nine wood species options, complemented by comprehensive stain libraries and specialized Olde World hand-distressed and Aged finish techniques. These kitchen cabinets Shiloh offerings extend beyond traditional applications, encompassing over 40 decorative wood hoods and custom furniture vanities that create cohesive design solutions from kitchen to bathroom.
“Our goal is to provide trade professionals with both exceptional products and the resources they need to succeed,” added Goksoy. “This collection combines premium materials with practical design flexibility, allowing our partners to offer their clients truly customized solutions while maintaining competitive project timelines.”
The Chantilly showroom, located at 14000 Thunderbolt Place, Suite K, is one of six NextDAY Cabinets locations throughout the region. The facility provides hands-on access to the complete product line, professional design consultation services, and direct support for contractors and builders working on residential and commercial projects.
NextDAY Cabinets specializes in wholesale distribution of all-wood kitchen cabinets and bathroom vanities, maintaining partnerships with leading manufacturers while offering low prices and three to five day lead times. The company provides comprehensive support services, including professional kitchen and bathroom design consultation, custom paint programs, and dedicated trade partner resources for contractors, dealers, and builders throughout the Mid-Atlantic region.
The Shiloh cabinetry brochure serves as a complete resource guide for trade professionals, providing detailed specifications, real-world door, finish, and species combinations, and comprehensive construction quality information. The document enables contractors and designers to streamline project planning and client consultations with accurate visual references and technical specifications.
###
For more information about NextDAY Cabinets Chantilly Showroom, contact the company here:
NextDAY Cabinets Chantilly Showroom Logan Goksoy +18004405948 info@nextdaycabinets.com 14000 Thunderbolt Pl ste.k, Chantilly, VA 20151, United States
Go Industries Inc, a Richardson, Texas-based truck accessories manufacturer, has introduced heavy-duty shovel boxes for trucks designed to provide efficient storage solutions for work vehicles. The new product features perforated metal construction that allows dirt and debris to fall through, preventing accumulation within the storage compartment.
The shovel boxes measure 72″ by 18″ by 10″ and are engineered for versatility in mounting options. Users can choose between permanent installation or a slide-in configuration for easy removal when needed. The perforated metal sides distinguish this storage solution from conventional enclosed boxes by addressing the common problem of dirt and debris buildup that typically occurs when storing shovels and other long-handled tools.
“The design philosophy behind our shovel boxes addresses a fundamental challenge that work truck operators face daily,” said a Go Industries spokesperson. “By incorporating perforated metal construction, we eliminate the maintenance issues associated with dirt accumulation while providing robust storage that withstands the demands of commercial and industrial applications.”
The product is available in both white and black finishes to complement various truck colors and fleet specifications. The installation process has been streamlined to accommodate both professional installers and truck owners who prefer to handle their own worktruck upgrades. The mounting system allows for secure attachment while maintaining the flexibility to adapt to different truck bed configurations.
Go Industries has established itself in the truck accessories market since 1978, developing products that serve commercial fleets, law enforcement agencies, and individual truck owners. The company’s product line extends beyond storage solutions to include grille guards, winch systems, bumper replacements, headache racks, and custom manufacturing services.
The introduction of these shovel boxes aligns with the company’s focus on creating practical solutions for work vehicles. Construction crews, landscaping companies, utility services, and agricultural operations represent key market segments that regularly require secure storage for long-handled tools and equipment.
“Work trucks serve as mobile offices and equipment centers for countless professionals,” added the Go Industries spokesperson. “Our shovel boxes represent one component of a comprehensive approach to maximizing truck functionality and organization.”
The perforated metal construction also contributes to weight reduction compared to solid-walled alternatives, while maintaining structural integrity. This design consideration impacts fuel efficiency and payload capacity, factors that fleet managers and owner-operators evaluate when selecting truck accessories.
Go Industries Inc. maintains its manufacturing operations in Richardson, Texas, where it produces a range of truck accessories and custom solutions. The company holds Platinum Status with SEMA, reflecting its commitment to quality standards and innovation in the automotive aftermarket industry. Beyond standard product offerings, Go Industries provides custom manufacturing services for clients with specific requirements that extend beyond catalog items.
The shovel boxes join an extensive catalog of truck accessories designed to enhance vehicle functionality, protection, and organization for professional and personal use.
###
For more information about Go Industries Inc, contact the company here:
Go Industries Inc Go Industries 800-527-4345 sales@goindustries.com Go Industries Inc 420 N Grove Rd Richardson, TX 75081
Pawn Jewelry is a trusted jewelry pawn shop serving Aventura, Florida, and clients nationwide. The company specializes in secure, professional, high-value pawn services for fine jewelry, luxury watches, diamonds, and gold. Known for its expertise in luxury goods and flexible loan options, Pawn Jewelry has built its reputation on transparent processes and convenient services. Aventura Market Director Sasha Gold who has more than a decade of experience in the high-end jewelry industry, leads the local team with a strong focus on accurate valuations and exceptional client relations
Pawn Jewelry is expanding its services to include enhanced pawning opportunities for Rolex watches. Already recognized for handling fine jewelry and luxury watches, the company is introducing specialized loan services designed to give Rolex owners access to higher loan amounts and faster funding. Whether clients own a Daytona, Submariner, Datejust, or Yacht-Master, these timepieces can now serve as powerful financial assets, offering a secure and efficient way to access capital. Pawn Jewelry sets itself apart with services that are both accessible and convenient. Clients can visit the Aventura location for in-person consultations or begin the process online from home. The online system is simple, transparent, and secure, allowing customers to submit information and receive initial evaluations quickly; insured shipping options and prompt payment by check or wire are available once an offer is accepted. For those searching for “Pawn Your Rolex to Pawn Jewelry in Aventura, FL,” the process at Pawn Jewelry is straightforward. Every step is explained clearly, and clients can be confident they are receiving maximum value for their items.
“Providing accessible financial services has always been at the core of our operations,” said a company representative. “Expanding our focus on iconic Rolex watches is a natural step, especially given the trust and demand from our clientele.” This dedication to customer service is central to the company’s success. Pawn Jewelry offers fair appraisals and secure transactions, ensuring clients feel confident and respected throughout the process. The goal is not only to provide immediate financial solutions but also to build lasting relationships based on integrity and professionalism.
Pawn Jewelry also provides comprehensive services for high-value items. Whether clients are pawning or selling luxury goods, the company promises clear, transparent valuations and a pressure-free experience. This commitment supports long-term customer satisfaction and trust. In addition to Rolex watches, Pawn Jewelry offers specialized services for high-end jewelry from well-known brands, as well as diamonds and gold. Each category receives expert attention, reflecting the team’s depth of knowledge in the luxury market. Clients can also start transactions online at PawnJewelry.com, with insured shipping to headquarters for final evaluation. “Emphasizing both online and in-store services is key to meeting the needs of our diverse client base,” a company spokesperson stated. “Whether someone needs topawn their Rolex to PawnJewelry.com or inquire about other items, our systems are designed to be user-friendly and efficient.”
While Pawn Jewelry is proudly based in Aventura, its services extend across the United States through its online platform and insured shipping options. This national reach ensures that clients in multiple regions can access the company’s expertise without compromising on service quality. By maintaining consistent processes and communication, Pawn Jewelry delivers a professional experience for every transaction, regardless of location. Pawn Jewelry’s enhanced range of services represents an important step in the company’s mission to offer reliable and high-value pawn solutions. With a special focus on Rolex watches, the company is meeting growing demand for quick, secure access to capital backed by luxury assets. The team’s consistent attention to accuracy, transparency, and client care has been integral to building a trusted name in luxury pawning.
By continuing to refine its online tools, expand its service capabilities, and uphold high standards for valuation and security, Pawn Jewelry remains a dependable choice for individuals looking for safe and fair pawn transactions. Clients interested in exploring these opportunities can learn more and start the process at PawnJewelry.com, where further information about pawning jewelry, luxury watches, diamonds, and gold is readily available.
###
For more information about Pawn Jewelry – Aventura, contact the company here:
Pawn Jewelry – Aventura Patricia Moose 573-875-2265 marketing@diamondbanc.com 19790 W Dixie Hwy Suite 1108-A, Miami, FL 33180
NEW YORK, NY / ACCESS Newswire / September 11, 2025 / From the start, recycling was pitched as the low-cost, high-impact fix for the planet’s plastic problem. And everyone played along. Governments rolled out bold targets, corporations committed vast sums, and watchdog groups pushed hard for results. Yet the outcome tells another story. Recycling rates remain flat, plastic waste continues to pile up, and confidence in the process has steadily eroded.
The problem was never a lack of effort or resources. It was that everyone was working inside a system that was flawed by design, making failure almost inevitable. That is why the announced partnership between SMX (NASDAQ:SMX) and Singapore’s A*STAR is such a turning point. Together, they are unveiling the world’s first national plastics passport, part of a system designed not to work around the flaws of recycling but to correct them at the foundation. What once failed because of weak design can now succeed because the structure itself is being rebuilt.
No one’s pointing fingers, here. The failures of recycling were never about intent but about a system that couldn’t scale. Fragmentation came first, with every country-and often every city-setting its own rules. What passed as recycled in one market could be rejected in another, leaving global companies unable to prove consistency.
Oversight was the next weakness, built on paperwork and sporadic audits that were subjective and easy to manipulate. Claims of recycled content amounted to little more than trust. Finally, the system’s scope was far too narrow. By focusing mainly on bottles and food packaging while ignoring industrial polymers, automotive resins, electronics, textiles, and construction materials, recycling was bound to remain marginal instead of transformative.
That is why the creation of a plastics passport matters, and why SMX’s Plastic Cycle Token (PCT) takes it further, turning proof of recycling into a verifiable, tradable asset that rewards participation across the supply chain.
Correcting The Fatal Design Flaws
Viewed together, the system flaws were not minor oversights but fatal design features. They explain why decades of investment and political will never managed to deliver the results promised. Without a redesign, recycling could never live up to its potential.
This is the context in which SMX’s technology delivers something new. By embedding invisible molecular markers directly into plastics, the company creates a plastics passport that travels with the material through its entire lifecycle. The passport establishes a consistent standard that applies whether the material is recycled in Europe, Singapore, ASEAN, or the United States. It replaces fragmentation with uniformity.
Better still, because the plastics passport is embedded immutably at the material level, oversight becomes a matter of proof rather than paperwork. Regulators and companies can verify recycled content instantly and continuously, without relying on subjective audits. And because SMX’s markers can be embedded in virtually any polymer, from packaging to industrial-grade plastics, the system around a circular economy standard finally expands beyond the narrow focus that doomed earlier attempts.
Singapore Steps Forward To Create The Standard
It is no surprise that Singapore is the first country to implement this vision on a national scale. The country has a track record of building frameworks that go on to shape international standards, from finance to digital infrastructure. Through A*STAR and SMX, Singapore’s mission to perpetuate the world’s first national plastics passport is once again setting the pace.
The ripple effects are already visible across ASEAN, where neighboring markets, with this new blueprint, see a clear path to replicate Singapore’s model. Analysts estimate that the opportunity tied to a plastics passport framework in Southeast Asia could exceed S$4.2 billion annually, built on certified recycled materials and platform adoption.
The timing could not be more urgent. Governments are under pressure to prove that environmental policies create measurable results. Brands are under pressure from consumers and investors to back up sustainability claims with hard evidence. Financial markets are hunting for companies that can convert compliance into economic value.
In each case, the plastics passport offers a solution that moves recycling from aspiration to infrastructure. Waste becomes verified feedstock, compliance becomes a defensible asset, and sustainability becomes something that can be measured, traded, and trusted. For the first time, recycling has a pathway to function as promised. SMX is the company making that historic shift possible, turning proof into the currency that can finally make circularity work.
Shunpoly.com. “How Much Plastic Is Wasted Each Year in Singapore?” Accessed 5 August 2025.
National Environment Agency (NEA). Waste-Statistics & Overall Recycling (interactive dashboard). Updated 2024; accessed 5 August 2025.
National Environment Agency (NEA). Mandatory Packaging Reporting portal. Accessed 5 August 2025.
Singapore Statutes Online. Environmental Public Health (Public Cleansing) Regulations – Incineration gate-fee schedule; revised 2024.
National Environment Agency (NEA). “New Licensing Regime for General Waste Disposal Facilities.” Technical brief & dialogue-session slides; 2024.
Nasdaq.com. “SMX Announces Planned Launch of World’s First Plastic Cycle Token.” Press release; 2024.
Yahoo! Finance. “SMX Plastic Cycle Token Is a Functional Market-Driven Solution…” News article; 2024.
Los Angeles Tribune. “Carbon Credits Had Their Day… Now the SMX Plastic Cycle Token…” Feature article; 2025.
National Environment Agency (NEA). Refuse Collection Fees for Households. Revised 2024; accessed 5 August 2025.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.
Denver, Colorado – September 11, 2025 – (PRESS ADVANTAGE) –
Denver-based window cleaning specialist Ease Your Panes is reminding homeowners about the importance of professional window maintenance as spring pollen season creates visibility challenges across the metro area. The company reports increased demand for residential window cleaning services as Colorado’s intense spring allergen levels leave windows coated with pollen, reducing natural light and compromising indoor air quality.
Spring pollen accumulation on windows represents more than an aesthetic concern for Denver residents. The combination of tree pollen, grass allergens, and dust particles creates a film on glass surfaces that blocks natural light and traps irritants against window panes. Professional cleaning becomes essential for maintaining clear views and healthy indoor environments during peak allergy season.
“Spring pollen in Denver creates unique challenges for window maintenance that many homeowners underestimate,” said David Ennis, spokesperson for Ease Your Panes Window Cleaning. “The combination of high altitude, intense UV exposure, and seasonal allergens means windows require specialized cleaning techniques to restore clarity and prevent long-term damage to the glass surface.”
The company utilizes eco-friendly cleaning solutions and advanced water-fed pole systems to address pollen buildup without introducing harsh chemicals into the environment. These methods prove particularly effective for Denver’s hard water conditions, which can leave mineral deposits when combined with pollen residue. Professional cleaning techniques ensure complete removal of allergens while protecting window surfaces from scratching.
Colorado’s mile-high altitude intensifies the impact of spring pollen on residential windows. The thinner atmosphere allows more UV radiation to reach glass surfaces, baking pollen and other contaminants onto windows when left untreated. This process can lead to permanent etching and cloudiness that reduces property values and necessitates costly glass replacement.
Window Cleaning with Ease Your Panes includes comprehensive inspection and treatment of all window types, from standard residential glass to specialty stained glass features. The company’s trained technicians handle multi-story homes and hard-to-reach windows safely, eliminating the risk of homeowner injuries from ladder accidents.
“Clean windows significantly impact both home value and quality of life,” added Ennis. “Natural light improves mood and productivity while reducing reliance on artificial lighting. For allergy sufferers, removing pollen from window surfaces helps create a healthier indoor environment during Denver’s challenging spring season.”
The timing of professional window cleaning proves crucial for Denver homeowners. Spring cleaning removes winter grime and road salt residue while preparing windows for summer’s intense sun exposure. Regular maintenance prevents the accumulation of contaminants that can permanently damage glass surfaces in Colorado’s extreme weather conditions.
Ease Your Panes serves residential and commercial properties throughout the Denver metropolitan area, offering window cleaning, gutter cleaning, solar panel cleaning, and seasonal services including Christmas light installation. The company maintains strict safety protocols and uses state-of-the-art equipment to deliver professional results while protecting property and personnel. Their commitment to eco-friendly practices aligns with Denver’s environmental initiatives, using biodegradable products and water conservation techniques that protect Colorado’s natural resources. To learn more, visit the Ease Your Panes website.
###
For more information about Ease Your Panes, contact the company here:
Ease Your Panes David Ennis 720-477-3273 dennis@easeyourpanes.com 3800 Buchtel Blvd., Suite 102683 Denver, CO 80250
AUSTIN, TX / ACCESS Newswire / September 11, 2025 / Interactive Strength Inc. (NASDAQ:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the Wattbike, CLMBR and FORME brands and pending acquirer of Sportstech, today announced that it has updated its investor FAQ’s on its investor website in response to shareholder questions about its increased guidance, recently announced Sportstech results and upcoming AGM proposals.
For more commentary, information and details on the rationale for and structure of the expected acquisition, please see TRNR’s investor presentation on the Company’s investor website as well as its required filings with the US Securities & Exchange Commission (SEC).
Interactive Strength Inc. (NASDAQ:TRNR) has established a leading portfolio of premium fitness brands – Wattbike, CLMBR, and FORME – that combine advanced hardware, smart technology, and immersive content to deliver exceptional training experiences for both commercial and home use.
Wattbike offers a range of high-performance indoor bikes that set the global standard in cycling. Known for unmatched accuracy, realistic ride feel, and advanced performance tracking, Wattbike is trusted by elite athletes, national teams, and fitness enthusiasts around the world.
CLMBR redefines the next-generation vertical climbing experience through its patented open-frame design and immersive touchscreen, delivering a high-intensity, low-impact workout that’s both efficient and effective.
FORME delivers strength, mobility, and recovery training through immersive content, performance-grade hardware, and expert coaching. Its wall-mounted systems include the Studio, a smart fitness mirror for guided programming and live 1:1 personal training, and the Lift, which adds smart resistance cable training-ideal for high-performance environments and sport-specific development.
From elite performance to everyday wellness, our ecosystem of performance-focused solutions delivers data-driven outcomes for athletes, fitness enthusiasts, and commercial operators.
Forward Looking Statements: This press release includes certain statements that are “forward-looking statements” for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements generally are accompanied by words such as “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the possibility of acquiring future businesses or completing the referenced pending transactions in a timely manner or at all, the performance or revenue growth of those businesses, the potential insulation from losses or potential gains related to cryptocurrencies or the commentary about the potential benefits or drawbacks of voting for a proposal at the Company’s AGM or the impact of reverse splits, Nasdaq listing rules or whether future payments in cash or common equity for acquisitions is more preferable or attractive. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Risks and uncertainties include but are not limited to: whether ATW Partners and / or DWF Labs will invest further amounts, other US publicly listed companies’ crypto strategies, and the price of $FET tokens. A further list and descriptions of these risks, uncertainties and other factors can be found in filings with the Securities and Exchange Commission. To the extent permitted under applicable law, the Company assumes no obligation to update any forward-looking statements.
One Billion People Living With Mental Health Conditions
ATLANTA, GA / ACCESS Newswire / September 11, 2025 / The World Health Organization (WHO) has issued an urgent call: more than one billion people worldwide are now living with mental health conditions such as anxiety and depression, costing the global economy an estimated US $1 trillion annually.
MentalHealth.com today reaffirmed its mission to meet this challenge head-on, building intelligent technology that empowers people and transforms access to care on a global scale.
“Our vision has always been to support the mental health of one billion people – the very scale the WHO has now identified as the global challenge before us,” said Patrick Nagle, Co-Founder of MentalHealth.com. “We are committed to building systems of care, support, and well-being to meet this need.”
Aligning with WHO’s Urgent Priorities
The WHO has outlined four immediate priorities: equitable financing, legal reforms, workforce investment, and person-centered care. MentalHealth.com’s platform directly supports these goals by:
Delivering advanced diagnostics with companion support services to guide people throughout their wellness journey.
Offering personalized wellness programs through its mental health portal, already serving over 10,000+ beta accounts.
“As humanity struggles with disconnection and numbness, MentalHealth.com embarks on a crucial mission to support the well-being of billions worldwide,” said Jeff Smith, Co-Founder and Venture Advisor. “This is a venture with meaning.”
Growth and Milestones
MentalHealth.com has seen extraordinary growth in response to global demand:
600%+ year-over-year growth
4+ million people reached annually through its platform
15+ active social media channels with over 2 million followers
A rapidly expanding professionals network, with thousands of new accounts added each month
With mental health conditions projected by the WHO to cost $6 trillion globally by 2030, MentalHealth.com is scaling solutions to transform crisis into healthier and more resilient communities.
“We will repurpose the very technology responsible for disempowerment, dependence, and illness into digital tools for empowerment, independence, and health,” said Dr. Jesse Hanson, Ph.D., Clinical Affairs Director and Co-Founder.
Through advanced diagnostics, personalized wellness programs, and a trusted network of professionals, MentalHealth.com makes care more human.
A Human-Centered Approach
Built on three pillars – reliable resources, accessible services, and nurturing communities – MentalHealth.com is developing the world’s most intelligent mental health technology. Its vision is to support the mental health of one billion people and, ultimately, the well-being of all eight billion worldwide.
This release is being retransmitted for extra exposure to downstream sites.
SHELTON, CT / ACCESS Newswire / September 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering (“LSX”) World Congress 2025 in Boston, MA.
Event Information:
Event
NanoViricides Presentation at the LSX World Congress, 2025, Boston, MA
Day & Date
Wednesday, September 17, 2025
Time
12:30 pm
Location
LSX Biotech ShowCase (Day 2), Thomas Michael Menino (Boston) Convention and Exhibition Center, Boston, MA.
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.
Dr. Diwan has several pre-scheduled meetings in the partnering sessions and will also be available for meetings during the Congress on September 16th and 17th outside his busy schedule.
NanoViricides’ Current Antiviral Drugs Pipeline
The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.
Our most advanced candidate, NV-387, is an ultra-broad-spectrum antiviral with potential activity against most respiratory human pathogenic viruses – and more, because it emulates the attachment receptor family of sulfated proteoglycans that over 90% of human viruses utilize.
Moreover, NV-387 is designed to shape-shift upon binding to the virus particle, in the process disrupting the virus particle and making it incapable of infection, as a complete chemical nanomachine that destroys the virus.
The revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections.
Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates. This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.
Continued redevelopment or “updating” of vaccines necessitated by the viral escape or drift has recurrently cost billions of dollars every year for Influenza as well as COVID. NV-387 promises to make such costly endeavors unnecessary, once this drug is approved by regulatory bodies.
NV-387 is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region. We already have received preliminary approval of the clinical protocol and the study and now we are working diligently to finish and submit the clinical trial application.
NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study.
Further, NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
Additionally, NV-387 has shown excellent effectiveness in lethal lung infection in a humanized (hCD150+ knock-in) mouse model by the Measles virus. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.
At present, there are no generally approved drugs for the treatment of RSV, MPox, or Measles. The latter two are orphan diseases in the USA and will be eligible for earning a “Priority Review Voucher” (PRV) from the US FDA plus several years of market exclusivity upon approval. Each PRV is currently thought to be worth $150 million to $350 million as a tradable asset.
Additionally, NV-387’s success in treating MPox is expected to make it feasible to achieve US FDA regulatory approval as a Smallpox therapeutic, a much-needed drug for the US Bioterrorism defense strategy, with potential lucrative US Government and International contracts for stockpiling in the range of several hundred millions of dollars, assuming NV-387 is successful in a Phase II clinical trial for MPox treatment.
The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.
NV-387 is expected to become an “emperic therapy” for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections.
NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection.
In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.
The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.
NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery
Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.
Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.
Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.
Life Science Executive Partnering (LSX) World Congress will be held on Sept 16-17, with Forums on Sept 15, 2025, at the Thomas Michael Menino Convention & Exhibition Center, Boston, USA.
What is LSX World Congress-USA ? LSX World Congress-USA is where innovators, investors and senior life science dealmakers in the LSX community connect, learn and partner. The Congress gathers leaders from the US biotech, medtech, and pharmatech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology. Empowering innovation, accelerating investment and facilitating partnering to shape the future of healthcare is the objective of LSX World Congress.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,355,000 shares of common stock, issued by the Company on May 29, 2025 (the “Existing Warrants”), at the existing exercise price of $2.20 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-287423). The closing of the offering is expected to occur on or about September 11, 2025, subject to satisfaction of customary closing conditions.
Roth Capital Partners is acting as the Company’s financial advisor for this transaction.
In consideration for the immediate exercise of the warrants for cash, the exercising holders will receive new Class I warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”). The new Class I warrants will be exercisable into an aggregate of up to 13,065,000 shares of common stock, will be exercisable beginning on the effective date of stockholder approval of the shares issuable upon exercise of the new warrants at an exercise price of $2.20 per share, and have a term of exercise equal to five years after the stockholder approval date. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 20 days of the closing to register the resale of the shares of common stock underlying the new Class I warrants issued in the private placement.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and for the treatment of chronic kidney disease.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Company Contacts
Mike Porter Investor Relations Porter LaVay & Rose Inc. Email: mike@plrinvest.com
NEW YORK, NY / ACCESS Newswire / September 11, 2025 / Recycling was supposed to be the easy win for sustainability. Policymakers set bold targets, global brands pledged billions, and NGOs pressed for accountability. Yet despite all that ambition, the results speak for themselves. Recycling rates remain stuck, plastics continue to pile up, and skepticism runs deep across the supply chain.
That gap between ambition and outcome is exactly what SMX (NASDAQ:SMX) and Singapore’s A*STAR are solving with the world’s first national plastics passport. By embedding proof at the molecular level, their system is designed to fix the very flaws that have undermined recycling for decades.
At the root of recycling’s failure is not intent but structure. The frameworks built decades ago were designed too narrowly, audited too loosely, and fragmented by geography. The outcome was inevitable.
Fragmentation came first. Each country, and often each city, created its own patchwork of rules and collection standards. What qualifies as recycled content in one jurisdiction might not in another. The result is a global marketplace where no one can agree on what is credible, making it impossible for multinational brands to prove consistent compliance.
Inconsistent auditing followed. Most systems rely on paperwork, certifications, or periodic inspections. These are subjective, easy to manipulate, and incapable of providing continuous proof. When a brand says its packaging contains 30% recycled content, regulators and consumers have little more than a trust-me statement to rely on. That lack of transparency undermines confidence in the entire loop.
The final flaw is scope. Recycling frameworks built around PET bottles and food-grade rPET were always destined to disappoint. PET accounts for only a fraction of global plastic use. The real volume sits in industrial polymers, automotive resins, electronics, textiles, and construction-grade plastics. By leaving those categories outside the system, recycling was guaranteed to remain an aspiration rather than a reality.
Taken together, these three flaws are not minor oversights. They are the fatal design features that explain why decades of effort have not produced the results policymakers and brands promised.
The Passport That Rebuilds the System
SMX enters the story not as another recycling company, but as the architect of a system designed to work. Its molecular-level marking technology, which creates a digital plastic passport for all types of plastics, fixes the very flaws that have kept recycling from becoming functional.
Instead of fragmenting, the plastics passport unifies. By embedding a molecular marker directly into materials, not applied after the fact, SMX creates a digital, in Singapore’s case, national plastics passport, that can be scanned and trusted across borders. What makes these plastics passports so compelling is that, whether in Singapore, Europe, or the United States, the same verification and proof standards hold true. The fractured marketplace finally has a consistent standard. And the company’s Plastic Cycle Token (PCT) adds financial incentives.
Instead of paper audits, the passport delivers proof. A polymer carrying an SMX marker can be tracked at every step of its lifecycle, from production through use to recycling and reuse. This continuous verification replaces subjective claims with objective evidence. Brands and regulators do not need to wait for quarterly disclosures or rely on audits that only sample small windows in time. Proof is present in the material itself.
All types. Instead of focusing nearly exclusively on PET or rPET, the SMX plastics passport expands coverage. SMX’s markers work across all polymer types, from high-performance plastics in electronics to resins used in construction and automotive industries. That expansion changes the math entirely. Recycling can finally address the full plastics economy rather than a sliver of it.
By the way, it is no coincidence that Singapore has become the first country to implement this vision on a national scale. They have led in other markets, structurally changing some in the financial sector. By working with A*STAR and SMX to launch a plastics passport program, Singapore is leading again, this time transforming the idea of recycling from patchwork experiments into national infrastructure. That leadership is already influencing ASEAN, where the region can see a tangible pathway to replicate Singapore’s framework into a market worth more than S$4.2 billion annually.
Why the Fix Matters Now
Those billions are the tip of the sustainability iceberg, making the stakes for getting this right never higher. Governments are under pressure to prove their environmental policies create a measurable impact. Brands are under pressure from consumers and investors to back up sustainability claims with real evidence. Financial markets are searching for companies that can turn compliance into value creation.
With SMX, plastics recycling shifts from aspiration to infrastructure. Waste becomes verified feedstock, compliance becomes a source of defensible value, and sustainability becomes measurable. For governments, this means accountability that functions across borders. For brands, it means proof that holds up to scrutiny. For stakeholders, it signals a company not simply aligned with a trend but positioned to own the architecture of a new system.
The fatal flaw in recycling was never ambition. It was design. Now, with an SMX plastics passport program built at the molecular level, the design itself has been fixed. Plastics recycling finally has the chance to work as promised, and SMX is the company making that historic correction possible.
Shunpoly.com. “How Much Plastic Is Wasted Each Year in Singapore?” Accessed 5 August 2025.
National Environment Agency (NEA). Waste-Statistics & Overall Recycling (interactive dashboard). Updated 2024; accessed 5 August 2025.
National Environment Agency (NEA). Mandatory Packaging Reporting portal. Accessed 5 August 2025.
Singapore Statutes Online. Environmental Public Health (Public Cleansing) Regulations – Incineration gate-fee schedule; revised 2024.
National Environment Agency (NEA). “New Licensing Regime for General Waste Disposal Facilities.” Technical brief & dialogue-session slides; 2024.
Nasdaq.com. “SMX Announces Planned Launch of World’s First Plastic Cycle Token.” Press release; 2024.
Yahoo! Finance. “SMX Plastic Cycle Token Is a Functional Market-Driven Solution…” News article; 2024.
Los Angeles Tribune. “Carbon Credits Had Their Day… Now the SMX Plastic Cycle Token…” Feature article; 2025.
National Environment Agency (NEA). Refuse Collection Fees for Households. Revised 2024; accessed 5 August 2025.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.
